Technology · 19/11/20261 min read
Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity
Summary
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 18, 2026 — Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today...